EXCLUSIVE: Novo Nordisk Faces Political Heat Over Weight-Loss Drug Prices Ahead Of Elections, Yet 'The Real Issue Is With The Middlemen'
EXCLUSIVE: Novo Nordisk Faces Political Heat Over Weight-Loss Drug Prices Ahead Of Elections, Yet 'The Real Issue Is With The Middlemen'
獨家：諾和諾德在選舉前因減肥藥物價格問題面臨政治壓力，但「真正的問題在於中間商」
Novo Nordisk A/S (NYSE:NVO) is under mounting political pressure over the high U.S. prices of its blockbuster weight-loss drugs, Ozempic and Wegovy, as the race for the White House heats up. The pricing disparity between the U.S. and other international markets has drawn sharp criticism from lawmakers, putting the company in the political spotlight.
諾和諾德（Novo Nordisk A/S，紐交所代碼：NVO）正面臨日益增加的政治壓力，其暢銷減肥藥物奧塞庇和維諾醫在美國的高價格引發了關注，而白宮角逐也越發激烈。美國與其他國際市場之間的定價差異引發了議員們的尖銳批評，使該公司成爲政治焦點。
Ozempic, for example, costs around $969 per month in the U.S., while the same drug is available for as low as $71 in France. Wegovy, another Novo Nordisk drug, is priced at $1,349 in the U.S., versus only $92 in the U.K...
例如，奧塞庇在美國每月的費用約爲969美元，而同一藥品在法國僅售71美元。另一種諾...
登入免費觀看全文
登入/註冊